Fight Over Waze? Way
Health Care: Drugs
Forest Laboratories Inc. (FRX: NYSE)
$39.23 -0.30 | -0.76%
05/24/13 - 04:03 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 39.53 |
| 52 Week High | 39.68 |
| 52 Week Low | 31.28 |
| Avg. Daily Vol. (Mil) | 1.36 |
| Beta (3 year) | 0.55 |
| Share Related Items | |
| Mkt Cap (Mil) | 10,526.22 |
| Shares Out (Mil) | 266.28 |
| Float (Mil) | 231.77 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.20 |
| Current Ratio | 3.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.40 |
| Price/Book | 1.86 |
| Price/Cash Flow | 40.70 |
| Per Share Data | |
| Earnings | -0.12 |
| Sales | 11.63 |
| Book Value | 21.29 |
| Cash Flow | 0.97 |
| Business Summary | |
|---|---|
| Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription. | |
| General Information | |
| 909 Third Avenue
New York, NY 10022-4731 |
|
| www.forestlaboratories.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 5700 | |
| CEO: Mr. Howard Solomon | |
| Short Interest | |
| Current Month (Mil) | 4.17 |
| Previous Month (Mil) | 4.27 |
| Short Interest Ratio (Days) | 3.10 |
| Management Effectiveness | |
| Return on Equity | 2.00 |
| Return on Assets | 1.50 |
| Return on Investments | 2.00 |
| Profitability | |
| Gross Margin | 83.60 |
| EBIT Margin | 4.10 |
| Profit Margin | -1.00 |
Portfolios with FRX
- Portfolio NameUser Type
- ProCarl Icahn
- UserMike Fatah's Companies with...
- ContributorStocks With Big Insider Buy...
- ContributorPharmaceutical Short Squeez...
- ContributorEarnings Short Squeeze Play...
- UserSm. Magic July 5 13
- UserLong Term Stock Picks
- UserRikedom
- Userjohnnystocks
- ProRichard Pzena - Pzena Inves...
Latest FRX Headlines from TheStreet
- Today's Drugs Industry Featured Laggard: Forest Laboratories Inc. (FRX) 04.16.13 | 05:04 pm
- Notable Two Hundred Day Moving Average Cross - FRX 04.16.13 | 04:04 pm
- 5 Stocks Pushing The Drugs Industry Downward 04.15.13 | 01:04 pm
- Forest Laboratories Becomes #183 Most Shorted S&P 500 Component, Replacing Allergan 04.10.13 | 03:04 pm
- Ziopharm Considers Options After Drug Failure 03.27.13 | 11:03 am
- Stock Futures Slide as Traders Eye Earnings 01.15.13 | 09:01 am
- Before the Bell, January 15
01.15.13 | 08:01 am - Forest Reaches New 52-Week High (FRX) 01.11.13 | 09:01 am
- Analysts' Actions: RIMM AIG AOL JCP FRX 01.11.13 | 09:01 am
- Forest Rises On Unusually High Volume (FRX) 11.30.12 | 04:11 pm
Press Releases for FRX
- From Perspectives To Struggles, Alzheimer's Family Caregivers Find Strength In Sharing - PR Newswire 02.05.13 | 10:02 am
- Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings - Business Wire 01.15.13 | 07:01 am
- Forest Laboratories, Inc. Announces Additional Settlement Agreement In BYSTOLIC® Patent Litigation - Business Wire 01.03.13 | 08:01 am
- Forest Laboratories, Inc. Sets Date And Conference Call For Fiscal 2013 Third Quarter Earnings - Business Wire 01.02.13 | 04:01 pm
- FACT SHEET -- Chronic Idiopathic Constipation - Business Wire 12.17.12 | 08:12 am
- Forest Laboratories And Almirall Announce Commercial Availability Of Tudorza™ Pressair™ In US Pharmacies - Business Wire 12.11.12 | 02:12 am
- Forest Laboratories, Inc. To Present Cariprazine Results From A Phase 3 Trial And Two Pharmacology Studies At The American College Of Neuropsychopharmacology (ACNP) Annual Meeting - Business Wire 12.03.12 | 05:12 pm
- Forest Laboratories, Inc. Announces Additional Settlement Agreements In BYSTOLIC® Patent Litigation - Business Wire 11.28.12 | 04:11 pm
- Forest Laboratories Submits New Drug Application For Cariprazine For The Treatment Of Both Schizophrenia And Manic Or Mixed Episodes Associated With Bipolar I Disorder - Business Wire 11.28.12 | 02:11 am
- Forest Laboratories And Adamas Pharmaceuticals Enter Into Licensing Agreement For The Development And Commercialization Of A Fixed Dosed Combination Of Namenda XR® And Donepezil For Alzheimer’s Disease - Business Wire 11.14.12 | 08:11 am
Partner Headlines for FRX
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- NIRI Appoints Charles Triano to Board of Directors - Benzinga 03.20.13 | 09:03 am
- UPDATE: Credit Suisse Raises PT to $44 on Forest Laboratories on Positive Linzess Survey - Benzinga 03.15.13 | 01:03 pm
- EU Approval for Ironwood's Constella - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 3 Undervalued Healthcare Stocks Being Sold By Hedge Funds - Seeking Alpha 11.29.12 | 09:11 am
- Data on Pfizer's Lyrica - Analyst Blog - Zacks 11.19.12 | 07:11 pm
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Earnings Scorecard: Forest Labs - Analyst Blog - Zacks 10.26.12 | 06:10 pm
- Pre-Market Earnings Report for October 16, 2012 : JNJ, KO, UNH, GS, PNC, STT, GWW, OMC, MAT, FRX, CBSH, DPZ - NASDAQ 10.15.12 | 08:10 pm
